Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound-guided transbronchial needle aspiration

Thoracic Cancer

Volumn 3, Issue 3, 2012, Pages 262-268

  Okada, Hironobu ^a   Anayama, Takashi ^a   Kume, Motohiko ^a   Hirohashi, Kentaro ^a   Miyazaki, Ryouhei ^a   Matsumoto, Manabu ^b   Orihashi, Kazumasa ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KOCHI MEDICAL SCHOOL HOSPITAL   (Japan)

Author keywords

EBUS TBNA; EGFR mutation; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LOCKED NUCLEIC ACID; PEPTIDE NUCLEIC ACID; SURFACTANT PROTEIN A; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; ECHOGRAPHY; ENDOBRONCHIAL ULTRASONOGRAPHY; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LYMPH NODE METASTASIS; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSBRONCHIAL ASPIRATION;

EID: 84864781050     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00122.x     Document Type: Article

References (27)

1. NSCLC Meta-analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-25.
2. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10 (Suppl.): 1-10.
3. Yang C-H, Shih J-Y, Chen K-C etal. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 2006; 107: 1873-82.
4. Morita S, Okamoto I, Kobayashi K etal. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493-8.
5. Paez JG, Jänne PA, Lee JC etal. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
6. Pao W, Miller V, Zakowski M etal. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
7. Mitsudomi T, Kosaka T, Endoh H etal. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
8. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
9. Rosell R, Moran T, Queralt C etal. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67.
10. Otani H, Toyooka S, Soh J etal. Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J Thorac Oncol 2008; 3: 472-6.
11. Horiike A, Kimura H, Nishio K etal. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007; 131: 1628-34.
12. Yasuda H, Soejima K, Nakayama S etal. Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. Lung Cancer 2011; 72: 32-8.
13. Yasufuku K, Chiyo M, Sekine Y etal. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004; 126: 122-8.
14. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines 2nd edition. Chest 2007; 132 (Suppl.): 131S-48S.
15. Lim E, Shah PL. Role of endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal lymph node staging of lung cancer. Thorac Cancer 2010; 1: 2-3.
16. Nakajima T, Yasufuku K, Suzuki M etal. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007; 132: 597-602.
17. Oshita F, Matsukuma S, Yoshihara M etal. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 2006; 95: 1070-5.
18. Garcia-Olivé I, Monsó E, Andreo F etal. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010; 35: 391-5.
19. Nagai Y, Miyazawa H, Huqun etal. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-82.
20. Tanaka T, Nagai Y, Miyazawa H etal. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007; 98: 246-52.
21. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 568-77.
22. Riquet M, Bagan P, Le Pimpec Barthes F etal. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg 2007; 84: 1818-24.
23. Keller SM, Vangel MG, Wagner H etal. Prolonged survival in patients with resected non-small cell lung cancer and single level N2 disease. J Thorac Cardiovasc Surg 2004; 128: 130-7.
24. Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) nonsmall cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg 2004; 127: 1100-06.
25. Riquet M, Assouad J, Bagan P etal. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg 2005; 79: 225-33.
26. Nicholson AG, McCormick CJ, Shimosato Y, Butcher DN, Sheppard MN. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Histopathology 1995; 27: 57-60.
27. Broers JLV, Ramaekers FCS, Rot MK etal. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988; 48: 3221-29.